WO2004002984A2 - Composes de maleimides marques, leur procede de preparation et leur utilisation pour le marquage de macromolecules - Google Patents
Composes de maleimides marques, leur procede de preparation et leur utilisation pour le marquage de macromolecules Download PDFInfo
- Publication number
- WO2004002984A2 WO2004002984A2 PCT/FR2003/002028 FR0302028W WO2004002984A2 WO 2004002984 A2 WO2004002984 A2 WO 2004002984A2 FR 0302028 W FR0302028 W FR 0302028W WO 2004002984 A2 WO2004002984 A2 WO 2004002984A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- formula
- group
- pyridin
- chosen
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 47
- 229920002521 macromolecule Polymers 0.000 title claims abstract description 39
- 125000005439 maleimidyl group Chemical class C1(C=CC(N1*)=O)=O 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 122
- 238000002059 diagnostic imaging Methods 0.000 claims abstract description 10
- 238000004458 analytical method Methods 0.000 claims abstract description 8
- 238000001514 detection method Methods 0.000 claims abstract description 7
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 6
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims abstract description 3
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims abstract description 3
- 125000002950 monocyclic group Chemical group 0.000 claims abstract description 3
- 238000003325 tomography Methods 0.000 claims abstract description 3
- 229910052720 vanadium Inorganic materials 0.000 claims abstract description 3
- -1 piridazinyl Chemical group 0.000 claims description 41
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 26
- KRHYYFGTRYWZRS-BJUDXGSMSA-N ac1l2y5h Chemical group [18FH] KRHYYFGTRYWZRS-BJUDXGSMSA-N 0.000 claims description 25
- 238000002372 labelling Methods 0.000 claims description 20
- 235000018102 proteins Nutrition 0.000 claims description 20
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 108090000623 proteins and genes Proteins 0.000 claims description 20
- 230000008569 process Effects 0.000 claims description 18
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 16
- 229910052736 halogen Inorganic materials 0.000 claims description 15
- 150000002367 halogens Chemical class 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- 235000018417 cysteine Nutrition 0.000 claims description 14
- 239000002243 precursor Substances 0.000 claims description 12
- 125000006239 protecting group Chemical group 0.000 claims description 12
- 229910052731 fluorine Inorganic materials 0.000 claims description 11
- 229910052740 iodine Inorganic materials 0.000 claims description 11
- 238000002600 positron emission tomography Methods 0.000 claims description 11
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 11
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 230000002285 radioactive effect Effects 0.000 claims description 10
- 150000001768 cations Chemical class 0.000 claims description 9
- 230000008878 coupling Effects 0.000 claims description 9
- 238000010168 coupling process Methods 0.000 claims description 9
- 238000005859 coupling reaction Methods 0.000 claims description 9
- VRTDLSPJKGTTLS-HSGWXFLFSA-N 1-[3-(2-fluoranylpyridin-3-yl)oxypropyl]pyrrole-2,5-dione Chemical compound [18F]C1=NC=CC=C1OCCCN1C(=O)C=CC1=O VRTDLSPJKGTTLS-HSGWXFLFSA-N 0.000 claims description 8
- 239000000460 chlorine Substances 0.000 claims description 8
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 8
- 108091034117 Oligonucleotide Proteins 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 125000003277 amino group Chemical group 0.000 claims description 7
- 125000003118 aryl group Chemical group 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- NLMDJJTUQPXZFG-UHFFFAOYSA-N 1,4,10,13-tetraoxa-7,16-diazacyclooctadecane Chemical compound C1COCCOCCNCCOCCOCCN1 NLMDJJTUQPXZFG-UHFFFAOYSA-N 0.000 claims description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 4
- 238000009007 Diagnostic Kit Methods 0.000 claims description 4
- 125000005100 aryl amino carbonyl group Chemical group 0.000 claims description 4
- 125000005110 aryl thio group Chemical group 0.000 claims description 4
- 125000004104 aryloxy group Chemical group 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 239000002739 cryptand Substances 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- LLAZQXZGAVBLRX-UHFFFAOYSA-N methyl 2,5-dioxopyrrole-1-carboxylate Chemical compound COC(=O)N1C(=O)C=CC1=O LLAZQXZGAVBLRX-UHFFFAOYSA-N 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims description 4
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical group [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 4
- MNESLHFFAVMPAT-UHFFFAOYSA-N trifluoromethanesulfonate;trimethylazanium Chemical compound C[NH+](C)C.[O-]S(=O)(=O)C(F)(F)F MNESLHFFAVMPAT-UHFFFAOYSA-N 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- 150000003863 ammonium salts Chemical class 0.000 claims description 3
- 230000006907 apoptotic process Effects 0.000 claims description 3
- 125000005129 aryl carbonyl group Chemical group 0.000 claims description 3
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims description 3
- 150000003983 crown ethers Chemical class 0.000 claims description 3
- 230000017074 necrotic cell death Effects 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 230000007170 pathology Effects 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 239000008096 xylene Substances 0.000 claims description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims description 2
- XJAOASFWMBFTNB-HSGWXFLFSA-N 1-[3-(6-fluoranylpyridin-3-yl)propyl]pyrrole-2,5-dione Chemical compound C1=NC([18F])=CC=C1CCCN1C(=O)C=CC1=O XJAOASFWMBFTNB-HSGWXFLFSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 2
- 239000012455 biphasic mixture Substances 0.000 claims description 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 2
- 229910052744 lithium Inorganic materials 0.000 claims description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 229910052701 rubidium Inorganic materials 0.000 claims description 2
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 229960002317 succinimide Drugs 0.000 claims description 2
- 125000006633 tert-butoxycarbonylamino group Chemical group 0.000 claims description 2
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 claims description 2
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims description 2
- 125000004306 triazinyl group Chemical group 0.000 claims description 2
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 claims description 2
- XPGHZJOCSIDYLD-DWSYCVKZSA-N 1-[2-(2-fluoranylpyridin-3-yl)oxyethyl]pyrrole-2,5-dione Chemical compound [18F]C1=NC=CC=C1OCCN1C(=O)C=CC1=O XPGHZJOCSIDYLD-DWSYCVKZSA-N 0.000 claims 1
- VYXWVWAUSOTSFA-UMSOTBISSA-N 1-[4-(2-fluoranylpyridin-3-yl)oxybutyl]pyrrole-2,5-dione Chemical compound [18F]C1=NC=CC=C1OCCCCN1C(=O)C=CC1=O VYXWVWAUSOTSFA-UMSOTBISSA-N 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- QJDDRPFCKYBNTR-UHFFFAOYSA-N trifluoromethanesulfonate;trimethyl-[3-[3-[(2-methylpropan-2-yl)oxycarbonylamino]propoxy]pyridin-2-yl]azanium Chemical compound [O-]S(=O)(=O)C(F)(F)F.CC(C)(C)OC(=O)NCCCOC1=CC=CN=C1[N+](C)(C)C QJDDRPFCKYBNTR-UHFFFAOYSA-N 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 abstract description 2
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 31
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 20
- 235000019439 ethyl acetate Nutrition 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 8
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 7
- 239000003480 eluent Substances 0.000 description 7
- 239000011630 iodine Substances 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 238000010511 deprotection reaction Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000011737 fluorine Substances 0.000 description 6
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 235000018977 lysine Nutrition 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000011894 semi-preparative HPLC Methods 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- 108010057281 Lipocalin 1 Proteins 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 150000001945 cysteines Chemical class 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 4
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 4
- VRTDLSPJKGTTLS-UHFFFAOYSA-N 1-[3-(2-fluoropyridin-3-yl)oxypropyl]pyrrole-2,5-dione Chemical compound FC1=NC=CC=C1OCCCN1C(=O)C=CC1=O VRTDLSPJKGTTLS-UHFFFAOYSA-N 0.000 description 3
- UEQRKEWMEMJXQO-UHFFFAOYSA-N 2-fluoropyridin-3-ol Chemical compound OC1=CC=CN=C1F UEQRKEWMEMJXQO-UHFFFAOYSA-N 0.000 description 3
- BBEKBFJKPANJTP-UHFFFAOYSA-N 3-(2-fluoropyridin-3-yl)oxypropan-1-amine Chemical compound NCCCOC1=CC=CN=C1F BBEKBFJKPANJTP-UHFFFAOYSA-N 0.000 description 3
- QHNWZNZLGYZMBX-UHFFFAOYSA-N 3-(2-fluoropyridin-3-yl)oxypropylcarbamic acid Chemical compound OC(=O)NCCCOC1=CC=CN=C1F QHNWZNZLGYZMBX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- HAFDLIPITLNEPG-UHFFFAOYSA-O trimethyl-[3-[3-[(2-methylpropan-2-yl)oxycarbonylamino]propoxy]pyridin-2-yl]azanium Chemical compound CC(C)(C)OC(=O)NCCCOC1=CC=CN=C1[N+](C)(C)C HAFDLIPITLNEPG-UHFFFAOYSA-O 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 0 **(C(C=C1)=O)C1=O Chemical compound **(C(C=C1)=O)C1=O 0.000 description 2
- OYJQXSHMEAATMV-UHFFFAOYSA-N 3-[2-(dimethylamino)pyridin-3-yl]oxypropylcarbamic acid Chemical compound CN(C)C1=NC=CC=C1OCCCNC(O)=O OYJQXSHMEAATMV-UHFFFAOYSA-N 0.000 description 2
- GRFNBEZIAWKNCO-UHFFFAOYSA-N 3-pyridinol Chemical group OC1=CC=CN=C1 GRFNBEZIAWKNCO-UHFFFAOYSA-N 0.000 description 2
- 235000006506 Brasenia schreberi Nutrition 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- HMSWAIKSFDFLKN-UHFFFAOYSA-N hexacosane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC HMSWAIKSFDFLKN-UHFFFAOYSA-N 0.000 description 2
- XMBWDFGMSWQBCA-OIOBTWANSA-N iodane Chemical group [124IH] XMBWDFGMSWQBCA-OIOBTWANSA-N 0.000 description 2
- 229940044173 iodine-125 Drugs 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000000163 radioactive labelling Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical group CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 150000003573 thiols Chemical group 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- AAMYWLSSLLJPAY-RVRFMXCPSA-N 1-((18F)fluoranylmethyl)-2-isothiocyanatobenzene Chemical compound [18F]CC1=C(C=CC=C1)N=C=S AAMYWLSSLLJPAY-RVRFMXCPSA-N 0.000 description 1
- JJUMPCWQAZUUAN-UHFFFAOYSA-N 1-(3-pyridin-3-yloxypropyl)pyrrole-2,5-dione Chemical class O=C1C=CC(=O)N1CCCOC1=CC=CN=C1 JJUMPCWQAZUUAN-UHFFFAOYSA-N 0.000 description 1
- CGNGRFYPWQMYJK-SJPDSGJFSA-N 1-[4-[(2-fluoranylpyridin-3-yl)oxymethyl]phenyl]pyrrole-2,5-dione Chemical compound [18F]C1=NC=CC=C1OCC1=CC=C(N2C(C=CC2=O)=O)C=C1 CGNGRFYPWQMYJK-SJPDSGJFSA-N 0.000 description 1
- PUQFGPKGPNQFNQ-HUYCHCPVSA-N 1-[5-(2-fluoranylpyridin-3-yl)oxypentyl]pyrrole-2,5-dione Chemical compound [18F]C1=NC=CC=C1OCCCCCN1C(=O)C=CC1=O PUQFGPKGPNQFNQ-HUYCHCPVSA-N 0.000 description 1
- XFCFAMUVKKYKCI-GKTGUEEDSA-N 1-[6-(2-fluoranylpyridin-3-yl)oxyhexyl]pyrrole-2,5-dione Chemical compound [18F]C1=NC=CC=C1OCCCCCCN1C(=O)C=CC1=O XFCFAMUVKKYKCI-GKTGUEEDSA-N 0.000 description 1
- VFRZXGFDZGDUJV-SQZVAGKESA-N 1-[[4-[(2-fluoranylpyridin-3-yl)oxymethyl]phenyl]methyl]pyrrole-2,5-dione Chemical compound [18F]C1=NC=CC=C1OCC(C=C1)=CC=C1CN1C(=O)C=CC1=O VFRZXGFDZGDUJV-SQZVAGKESA-N 0.000 description 1
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
- QJXCFMJTJYCLFG-UHFFFAOYSA-N 2,3,4,5,6-pentafluorobenzaldehyde Chemical compound FC1=C(F)C(F)=C(C=O)C(F)=C1F QJXCFMJTJYCLFG-UHFFFAOYSA-N 0.000 description 1
- OHJWOZBNEHQSJQ-HSGWXFLFSA-N 2,5-diamino-1-[4-((18F)fluoranylmethyl)phenyl]pentan-1-one Chemical compound [18F]CC1=CC=C(C(=O)C(CCCN)N)C=C1 OHJWOZBNEHQSJQ-HSGWXFLFSA-N 0.000 description 1
- UQENCUMESUUCBP-UHFFFAOYSA-N 2-(dimethylamino)pyridin-3-ol Chemical compound CN(C)C1=NC=CC=C1O UQENCUMESUUCBP-UHFFFAOYSA-N 0.000 description 1
- BMTSZVZQNMNPCT-UHFFFAOYSA-N 2-aminopyridin-3-ol Chemical compound NC1=NC=CC=C1O BMTSZVZQNMNPCT-UHFFFAOYSA-N 0.000 description 1
- ZZYHDHJFXLJNLN-UHFFFAOYSA-N 2-azido-2-fluoro-1-phenylethanone Chemical compound FC(C(C1=CC=CC=C1)=O)N=[N+]=[N-] ZZYHDHJFXLJNLN-UHFFFAOYSA-N 0.000 description 1
- ZJFWCELATJMDNO-LMANFOLPSA-N 2-bromo-1-(4-fluoranylphenyl)ethanone Chemical compound [18F]C1=CC=C(C(=O)CBr)C=C1 ZJFWCELATJMDNO-LMANFOLPSA-N 0.000 description 1
- AUFVJZSDSXXFOI-UHFFFAOYSA-N 2.2.2-cryptand Chemical compound C1COCCOCCN2CCOCCOCCN1CCOCCOCC2 AUFVJZSDSXXFOI-UHFFFAOYSA-N 0.000 description 1
- QIQDJNUUWYCZFZ-COJKEBBMSA-N 3-(18F)fluoranyl-5-nitrobenzamide Chemical compound C1=C(C=C(C=C1[N+](=O)[O-])[18F])C(=O)N QIQDJNUUWYCZFZ-COJKEBBMSA-N 0.000 description 1
- QHNWZNZLGYZMBX-LMANFOLPSA-N 3-(2-(18F)fluoranylpyridin-3-yl)oxypropylcarbamic acid Chemical compound [18F]C1=NC=CC=C1OCCCNC(O)=O QHNWZNZLGYZMBX-LMANFOLPSA-N 0.000 description 1
- AVLSIVRMKUJWIP-UHFFFAOYSA-N 3-(2-nitropyridin-3-yl)oxypropylcarbamic acid Chemical compound OC(=O)NCCCOC1=CC=CN=C1[N+]([O-])=O AVLSIVRMKUJWIP-UHFFFAOYSA-N 0.000 description 1
- QBPDSKPWYWIHGA-UHFFFAOYSA-N 3-hydroxy-2-nitropyridine Chemical compound OC1=CC=CN=C1[N+]([O-])=O QBPDSKPWYWIHGA-UHFFFAOYSA-N 0.000 description 1
- YMKBFDMRGWLFIS-UHFFFAOYSA-N 3-pyridin-3-yloxypropan-1-amine Chemical compound NCCCOC1=CC=CN=C1 YMKBFDMRGWLFIS-UHFFFAOYSA-N 0.000 description 1
- ZTKJZCCTWJQEMA-UHFFFAOYSA-N 3-pyridin-3-yloxypropylcarbamic acid Chemical compound OC(=O)NCCCOC1=CC=CN=C1 ZTKJZCCTWJQEMA-UHFFFAOYSA-N 0.000 description 1
- BBYDXOIZLAWGSL-COJKEBBMSA-N 4-fluoranylbenzoic acid Chemical compound OC(=O)C1=CC=C([18F])C=C1 BBYDXOIZLAWGSL-COJKEBBMSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- ZCYVEMRRCGMTRW-AHCXROLUSA-N Iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-AHCXROLUSA-N ac1l4zwb Chemical compound [76BrH] CPELXLSAUQHCOX-AHCXROLUSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-FTXFMUIASA-N bromine-75 Chemical compound [75BrH] CPELXLSAUQHCOX-FTXFMUIASA-N 0.000 description 1
- CPELXLSAUQHCOX-NJFSPNSNSA-N bromine-82 Chemical compound [82BrH] CPELXLSAUQHCOX-NJFSPNSNSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000003682 fluorination reaction Methods 0.000 description 1
- 229910052733 gallium Inorganic materials 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000010829 isocratic elution Methods 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 150000002669 lysines Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- KAIQZAZSOJBMMK-UHFFFAOYSA-N n-(3-hydroxypropyl)-2,2-dimethylpropanamide Chemical compound CC(C)(C)C(=O)NCCCO KAIQZAZSOJBMMK-UHFFFAOYSA-N 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- GRJJQCWNZGRKAU-UHFFFAOYSA-N pyridin-1-ium;fluoride Chemical compound F.C1=CC=NC=C1 GRJJQCWNZGRKAU-UHFFFAOYSA-N 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 229910052713 technetium Inorganic materials 0.000 description 1
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
- XDJCYKMWJCYQJM-UHFFFAOYSA-N tert-butyl n-(3-hydroxypropyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCO XDJCYKMWJCYQJM-UHFFFAOYSA-N 0.000 description 1
- ZXPICBHQSQCKMK-UHFFFAOYSA-N tert-butyl n-(3-pyridin-3-yloxypropyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCOC1=CC=CN=C1 ZXPICBHQSQCKMK-UHFFFAOYSA-N 0.000 description 1
- SYUSCVDPAABTPU-UHFFFAOYSA-N tert-butyl n-[3-(2-nitropyridin-3-yl)oxypropyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCOC1=CC=CN=C1[N+]([O-])=O SYUSCVDPAABTPU-UHFFFAOYSA-N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Definitions
- the present invention relates to maleimide compounds labeled with fluorine-18.
- the invention also relates to a process for the preparation of these compounds.
- the invention finally relates to the use of these maleimide compounds, in particular labeled with fluorine-18, for the labeling of. macromolecules, such as oligonucleotides, proteins, antibodies and peptides.
- the technical field of the invention can be defined, in general, as that of radioactive labeling of macromolecules and, in particular, of proteins and peptides.
- macromolecules such as proteins or even peptides can be coupled to a labeling molecule allowing their detection, this labeling molecule can be, for example, a fluorescent molecule, gold particles, a paramagnetic compound or a molecule carrying a radioelement.
- Proteins have been radioactively labeled with radioisotopes, iodine and various metal radioisotopes, such as technetium, indium and gallium. More recently, proteins have been labeled with fluorine-18.
- peptides coupled to radioelements allow "in vivo" detection of the localization of thrombotic zones during vascular accidents of all kinds, in particular apoptotic and inflammatory foci, using systems of imaging.
- radioactive atoms emitting positrons with a short lifespan and in particular 18 F can, in particular, be detected by positron emission tomography (PET) devices (PET or “Positon Emission Tomography”).
- PET positron emission tomography
- Radioactive labeling with fluorine-18 poses, in particular due to the very short period of fluorine-18 (close to 109.8 minutes), specific problems which make labeling with fluorine-18 fundamentally different from that with other halogens, such as iodine.
- the above coupling can be carried out by all the conventional techniques of organic chemistry known to those skilled in the art, and by the synthesis of protein and peptide markers carrying one or more radioactive atoms with a short lifespan, in particular 18 F.
- This marker generally consists, on the one hand, of a part capable of receiving, for example, an 18 F atom and, on the other hand, of a part comprising any conventional function of binding to the macromolecule, by for example, protein.
- These markers must meet the requirement for rapid and easy synthesis, because due to the short lifespan of radioisotopes such as 18 F, the duration of synthesis should not generally exceed a few hours.
- the methods for labeling proteins or peptides with fluorine-18 make use of markers also called “conjugated” or “synthon” labeled, which are classified into three main families, depending on whether they react with the amino groups, sulfhydryl groups, or carbohydrate groups of macromolecules, such as proteins and peptides.
- imidates such as 3- [ 18 F] fluoro-5-nitrobenzoimidate, which react, for example, with the ⁇ -NH 2 group of lysine to bind to a protein
- activated esters such as
- N-succinimidyl- [ 18 F] fluorobenzoate N-succinimidyl- [ 18 F] fluorobenzoate
- carboxylic acids such as N- (4- [ 18 F] fluorobenzoic acid
- aldehydes such as 4- [ 18 F] pentafluorobenzaldehyde
- isothiocyanates such as 4- ([ 18 F] fluoromethyl phenylisothiocyanate).
- Activated halides such as (4- [ 18 F] fluorophenacyl bromide), react with groups amino, such as the ⁇ -NH 2 group of lysine or the -SH group of cysteine.
- Amines such as 1- (4- ([ 18 F] fluoromethyl) benzoyl) -aminobutane-4-amine react with the CO 2 H groups, for example glutamic acid or aspartic acid or with CHO groups of glycoproteins.
- Nitrenes with photochemical active centers such as azidophenacyl fluoride [ 18 F] also react with amino groups, for example the ⁇ -NH 2 group of lysine.
- Two more specific methods for labeling peptides and nucleotides have good specificity with respect to sulfur atoms, for example cysteine for the peptides and a phosphoro-thioate function for the nucleotides.
- the first of these compounds is not easy to label with fluorine-18 with high specific activity.
- fluorine F 2 would allow easy labeling of (as with iodine) and it is precisely that F 2 is generally a product with low specific activity.
- F 2 is not suitable for the manufacture of so-called “radiotracers” compounds which are preferably targeted according to the invention, simply because the injected mass of labeled molecule becomes large and that, then, the basic principle governing this “tracer”, ie the extremely low occupation (for example, less than 5%) of the receiving sites, is not respected.
- the second of the compounds cited in the document by SHIUE et al. has an amide chain which is not chemically very solid and which is easily cleaved, broken, in vivo.
- X is a radioactive halogen chosen from bromine-75, bromine-76, bromine -82, iodine-123, iodine-125, iodine-131 and fluorine-18.
- the chemistry used to manufacture the fluorinated compound of document US Pat. No. 4,735,792 is a complex and long-term chemistry.
- the object of the present invention is to provide a fluorine-18 labeled maleimide compound which meets, among other things, these needs.
- the aim of the present invention is also to provide a fluorine-18 labeled maleimide compound which does not have the drawbacks, defects, limitations and disadvantages of the compounds of the prior art and which solves the problems of the prior art.
- n represents an integer from 1 to 10, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;
- Y represents a group chosen from monocyclic or bicyclic heterocyclic groups chosen from imidazolyl, pyrazolyl, benzimidazolyl, pyridinyl, piridazinyl, pyrimidinyl, pyrazinyl, triazinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, quinoxalinyl, possibly quinoxalinyl substituted by one or more substituents each of said substituents being independently selected from hydrogen, halogen (non-radioactive), phenyl, alkyl C ⁇ - 6 alkoxy C ⁇ - 6, aryloxy, amino, mono- or di (alkyl C ⁇ _ 6) alkylamino, mono- or di (aryl) amino, thio, alkyl C ⁇ - 6 alkylthio, arylthio, formyl, alkyl C ⁇ - 6 alkylcarbonyl, arylcarbonyl,
- - a, b, c, d, e, f, g each independently represent an integer of 0 to 10, such as 0, 1, 2, 3, 4, 5, 6, 7, 8, 9;
- halogen means fluorine, chlorine, bromine or iodine.
- C ⁇ _ 6 alkyl corresponds to saturated hydrocarbon radicals with linear and branched chains having from 1 to 6 carbon atoms, such as methyl, ethyl, propyl, butyl, pentyl and hexyl.
- the attachment and substitution of heterocycles, aryl group, etc., can be done at any position.
- the attachment of 18 F to Y or X can be done at any position, in particular at any position on a heterocycle.
- n 1, and Y is a 3-pyridinyl group.
- the compounds of formula (I) can belong to various families, a first family can be defined as that of "alkyl ethers", which correspond to the following formula (II):
- a second family of compounds of formula (I) can be defined as those of “phenylalkyl ethers”, which correspond to the following formula (III):
- q and r independently represent an integer from 0 to 10, such as 0, 1, 2, 3, 4, 5, 6, 7, 8, 9.
- a third family is that of the compounds which correspond to the following formula (IV):
- a preferred compound of formula (IV) is the following compound:
- a fourth family is that of the compounds which correspond to the following formula (V):
- Preferred compounds of formula (V) are the following compounds:
- the compounds according to the invention differ fundamentally from the compounds of the prior art, because of their specific structure in which the part carrying the atom of fluorine-18 is constituted, according to the invention, by a specific group Y which is in particular a pyridinyl group, the linking part, of coupling to a macromolecule, such as a protein or a peptide, is constituted, according to the invention by a specific function, namely a maleimido function, and, finally, the part of bond to a macromolecule and the part carrying the fluorine-18 atom are linked according to the invention by a new specific chain or spacer arm, for example of the alkyl type (generally from 2 to 6C), alkyl ether, ethers phenylalkyl, alkenyl, which are not fragile and are not susceptible to ruptures "in vivo".
- the invention relates to the use of a compound, as described above for labeling macromolecules.
- This macromolecule can be any macromolecule, in particular known biological, but it can be chosen, for example, from the oligonucleotides, proteins, antibodies and peptides. Said macromolecule is advantageously a macromolecule for recognizing a specific site chosen, preferably, from sites presenting target molecules specific for a pathology, such as sites of apoptosis, necrosis or tumor area.
- the invention also relates to a complex comprising a macromolecule coupled to a compound according to the invention, as described above.
- Said macromolecule is preferably chosen from oligonucleotides, proteins, antibodies and peptides.
- Said coupling is carried out by reaction of the double bond of the maleimido group of the compound according to the invention with specifically an -SH (thiol) function of cysteine in the case of a peptide, or a phosphoro-thioate function in the case of an oligonucleotide.
- cysteines are due to the presence in the molecule of the invention of a “dedicated” function, namely the maleimido function, which is a dedicated function for chemoselectivity towards the thiols of cysteines , or in a similar manner towards the phosphoro-thioate functions.
- a “dedicated” function namely the maleimido function, which is a dedicated function for chemoselectivity towards the thiols of cysteines , or in a similar manner towards the phosphoro-thioate functions.
- the labeling or coupling, via cysteine can be a direct labeling or coupling, that is to say that the cysteine already exists in the macromolecule which it is desired to couple to the compound according to the invention, either cysteine or a molecule (peptide) comprising it, can be introduced (coupled beforehand or not with the compounds of the invention) in the macromolecule which did not contain cysteine and coupling is then carried out if this has not been carried out beforehand cysteine or the molecule comprising it.
- the cysteine or molecule comprising it can, for example, be introduced "on order" into the macromolecule by engineering proteins / peptides in a position which does not compete with, or does not disturb the biological function.
- Said macromolecule is advantageously a macromolecule for recognition of a specific site, as described above.
- the coupling that is to say the labeling, is preferably such that it does not affect the recognition activity of the target, of the site, by the macromolecule.
- the invention also relates to an analysis and detection kit, for example for imaging medical comprising a compound according to the invention and a macromolecule.
- the invention also relates to an analysis and detection kit, for example for medical imaging, comprising a compound according to the invention coupled to a macromolecule, that is to say a complex according to the invention.
- the invention also relates to a diagnostic kit comprising a compound according to the invention and a macromolecule.
- the invention further relates to a diagnostic kit comprising a complex, as described above.
- the invention relates to the use of the complex or the compound, as described above, in a medical imaging method, such as positron emission tomography (PET) and the use of a complex or a compound according to the invention for manufacturing a product intended for medical imaging, for example for positron emission tomography (PET).
- a medical imaging method such as positron emission tomography (PET)
- PET positron emission tomography
- PET positron emission tomography
- the invention relates to a product for medical imaging, in particular positron emission tomography (PET) comprising a complex or a compound as described above and a pharmaceutically acceptable vehicle.
- PET positron emission tomography
- the compounds and complexes, according to the invention, comprising an atom of fluorine-18 show numerous advantages over the compounds with another radioactive halogen, for example iodine. Indeed, the only isotope of the positron emitting iodine is iodine-124, which could allow PET.
- iodine-124 is not a pure positron emitter (unlike fluorine -18.97%) and decreases by beta + emission at only 25% and by electronic capture at 75%; it has a large number of gamma lines ranging from 0.603 MeV (62%) to 2.75 MeV (1%).
- the invention also relates to a process for the preparation of a compound of formula (I), as described above, in which: a) a precursor compound of formula (la) is brought into contact:
- PRi and PR 2 independently represent a hydrogen atom or a group protecting the amino function, provided that PRi and PR 2 are not both (simultaneously) a hydrogen atom, or PRi and PR 2 together with the nitrogen atom form a cyclic protecting group for the amino function
- Gp represents a leaving group capable of being replaced by a fluorine atom
- 18 and X, Y, m and n have the meaning already given more high ; with a source of fluoride ions F " marked with [ 18 F], to give a compound of formula (Ib):
- the method according to the invention is simple, reliable, easy to implement and can be easily robotized. It only has three steps, one of which is an extremely simple deprotection step.
- the overall duration of the process is short: for example, it is generally from 60 to 120 minutes, preferably from 75 to 85 minutes.
- the incorporation of the halogen fluor-18 is carried out extremely efficiently with a high yield, for example 70 to 100%, because, in particular, it is carried out on a heterocyclic group, such as pyridine.
- the final yield of the whole process for a purified product is extremely high, for example from 15% to 25% and the potential quantities of “synthon” compound, at the end of the synthesis, are also very large.
- the groups PR 1 and PR 2 when they are protective groups can be any protective group known in organic chemistry. They are preferably chosen from the tert-butoxycarbonyl (BOC) and fluorenylmethoxy carbonyl (FMOC) groups.
- this protective group can be, for example, a pthalimido group.
- the group Gp may be any leaving group capable of being replaced by a fluorine-18 atom; Gp is preferably chosen from halogens, such as F, Cl, Br, I, mesyl, tosyl and triflate groups, when Y is an alkyl group; and Gp is preferably chosen from halogens, ammonium salts, such as trimethylammonium-trifluoromethane sulfonate, and the nitro group, when Y is an aromatic or heterocyclic group.
- halogens such as F, Cl, Br, I, mesyl, tosyl and triflate groups
- Y is an alkyl group
- Gp is preferably chosen from halogens, ammonium salts, such as trimethylammonium-trifluoromethane sulfonate, and the nitro group, when Y is an aromatic or heterocyclic group.
- the source of fluoride ions marked with 18 F comprises said fluoride ions and a counterion, chosen from large cations, such as rubidium, and tetrabutylammonium, and small cations , such as potassium, sodium and lithium, said small cations being trapped, stabilized, for example, by a cryptand or a crown ether, etc., said cryptand or crown ether being adapted to the small cation used.
- a counterion chosen from large cations, such as rubidium, and tetrabutylammonium
- small cations such as potassium, sodium and lithium
- KRYPTOFIX ® K 222 (4, 7, 13, 16, 21, 24-hexaoxa-1,10-diazabicyclo [8.8.8] hexacosane) which traps, for example, potassium ion.
- the counterion or cation can be brought in the form of any salt, for example, it can be K 2 C0 3 , in the case of potassium.
- Step a) is generally carried out in a solvent, which can be any suitable solvent, such as DMSO.
- Step a) can be carried out under conditions known to a person skilled in the art, with heating generally at a temperature of 50 to 200 ° C., for example, 145 ° C., for a duration generally of 1 to 30 minutes, for example from 4 to 6 minutes.
- Step b) of removal of the protective group from the amino function, of deprotection, to give the compound of formula (Ic), where the amino group is free can be carried out by any known deprotection method. It is possible, for example, to put the compound (Ib) in contact with TFA in CH 2 C1 2 for a duration generally of 1 to 5, for example of 2 minutes.
- the reagent capable of giving a maleimido group from an amido group can be any known compound. It can thus be chosen from N-methoxycarbonylmaleimide and succinimide.
- Step c) can be carried out under conditions known to a person skilled in the art, for example in a solvent, such as xylene, THF, with heating generally at a temperature of 100 to 200 ° C., for example 190 ° C, for a period of 1 to 20 minutes, for example 5 minutes.
- a solvent such as xylene, THF
- Step c) can in another embodiment also be carried out in a two-phase mixture for example of dioxane and aqueous sodium bicarbonate, at room temperature for a period of 3 to 15 minutes, for example 10 minutes;
- This mode of implementation of step c) offers the advantage of better performance and be implemented at room temperature, without the need to heat the mixture.
- the compound of formula (la) can correspond to the following formula (IIa):
- the compound (Ha) preferably corresponds to the following formula (11b):
- the compound of formula (la) can, in another embodiment, correspond to the following formula (Illa):
- the compound (Illa) preferably corresponds to the following formula (Illb):
- the compound of formula (la) can, in yet another embodiment, correspond to the following formula (IVa):
- the compound (IVa) preferably corresponds to the following formula (IVb):
- the compound of formula (la) can correspond to the following formula (Va):
- the compound (Va) preferably corresponds to the following formula (Vb):
- the invention also relates to the precursor compounds of formulas (la), (lia), (Ilb), (Illa),
- the precursor compounds can be chosen, in particular, from the final compounds defined, listed above, in which the [ 18 F] is replaced by a non-radioactive halogen, such as 19 F, Cl, Br, I, a salt d ammonium, such as trimethylammonium-trifluoromethanesulfonate or an NO 2 group and the group l-pyrrole-2,5-dione is replaced by a tert-butoxycarbonylamino group.
- a non-radioactive halogen such as 19 F, Cl, Br, I
- a salt d ammonium such as trimethylammonium-trifluoromethanesulfonate or an NO 2 group
- the group l-pyrrole-2,5-dione is replaced by a tert-butoxycarbonylamino group.
- Preferred precursor compounds are, for example [3- (3-tert-butoxycarbonylamino-propoxy) - pyridin-2-yl] -trimethyl-ammonium, trifluoromethane sulfonate; and [3- (2-nitro-pyridin-3-yloxy) -propyl] -carbamic acid tert-butyl ester.
- the chemicals were obtained from various suppliers (ALDRICH, FLUKA or SIGMA France) and they were used without further purification, except when mentioned.
- the TLCs are carried out on plates coated, beforehand, with silica gel 60F 2 5 from MERCK.
- the compounds were located (1) if possible at 254 nm, using a UV lamp and / or (2) by iodine staining and / or (3) by soaking the TLC plates in an ethanolic solution at 1 % ninhydrin (or a 1% aqueous solution of KMn0 4 ) and by heating on a hot plate. Radioactive points, spots or "spots" are detected using a BERTHOLD TRACE MASTER 20 automatic linear analysis device.
- the NMR spectra are recorded on a BRUKER AMX device (300 MHz), using the hydrogenated residue of deuterated solvents (DMS0-d 6 , ⁇ : 2.50 ppm; CD 2 C1 2 , ⁇ : 5.32 ppm; CD 3 OD , ⁇ : 4.78; CD 3 CN, ⁇ : 1.93 ppm) and / or TMS as internal standards for 1 H NMR, and deuterated solvents (DMS0-d 6; ⁇ : 39.5ppm; CD 2 C1 2 , ⁇ : 53.8 ppm; CD 3 OD, ⁇ : 49.3 ppm) and / or TMS, as internal standards for 13 C NMR.
- deuterated solvents DMS0-d 6; ⁇ : 39.5ppm; CD 2 C1 2 , ⁇ : 53.8 ppm; CD 3 OD, ⁇ : 49.3 ppm
- MS are measured on a Quadripolair Finnigan 4 600 (DCI / NH 4 + ).
- Aqueous fluoride [ 18 F] ions were prepared in a CGR-MeV 520 cyclotron by irradiation of a 2 mL water target, using a 20 MeV proton beam on water enriched in [ 18 0 ] to 95% by the nuclear reaction [ 18 0 (p, n) 18 F].
- the fluoride ions were transferred to the appropriate shielded cell.
- the radiosyntheses using fluor-18, including the purifications by semi-preparative HPLC were carried out in a 7.5 cm cell shielded with lead, using a ZYMATE robot system controlled by computer (from ZYMACK CORP., USA) .
- activation in the microwave is carried out with a MICRO ELL 10 oven (2.45 GHz), supplied by LAB ELL AB, Sweden.
- the specific radioactivity is determined as follows: the area of the UV absorbance peaks, corresponding to the radiolabelled product, is measured on the HPLC chromatogram and compared to a standard curve giving the mass, as a function of the UV absorbance.
- Example 2 The procedure described above in Example 1 is used with the 2-fluoro-3-hydroxypyridine prepared in Example 4 (1.29 g; 11.4 mmol) to give 1.9 g (62%) of tertiary butyl ester of [3- (2-fluoro-pyridin-3-yloxy) -propyl] -carbamic acid in the form of a yellow oil, after “flash” chromatography (eluent: CH 2 C1 2 pure, heptane / EtOAc: 70/30 to 50/50). Rf (CH 2 CL 2 / EtOAc: 95/5): 0.45.
- Example 2 The procedure described above in Example 2 is used with the tert-butyl ester of [3- (2-fluoro-pyridin-3-yloxy) -propyl] - carbamic acid prepared in a) (1, 0 g; molecular weight: 270.30; 3.7 mmol) to give 1.4 g / 95%) of 3- (2-fluoro-pyridin-3-yloxy) - propylamine. 2 TFA, in the form of a yellow oil.
- Example 2 The procedure described above in Example 1 is used with 2-dimethylamino-3-hydroxypyridine (0.250 g; molecular weight: 138.17; 1.8 mmol) to give 0.290 g of the tert-butyl ester of [3- (2-dimethylamino-pyridin-3-yloxy) -propyl] -carbamic acid (58%) as a yellow oil after “flash” chromatography (eluent: heptane / EtOAc: from 70/30 to 50/50).
- the tertiary butyl ester of [3- (2-dimethylamino-pyridin-3-yloxy) -propyl] -carbamic acid is then diluted in toluene (2 ml per 100 mg of ester) and the solution is cooled to 0 ° C (ice bath). To this solution is added methanetrifluoromethanesulfonate (50 microliters for 100 mg of ester) and the reaction medium is stirred for 1 hour at 0 ° C.
- DMSO freshly distilled (600 ⁇ L), containing 4.0 to 6.0 mg of the marker precursor “nitro” (tert-butyl ester of [3- (2-nitro-pyridin-3-yloxy) -propyl acid) ] -carbamic) is added directly to the tube containing the dried K [ 18 F] -K 222 complex.
- the tube (unsealed) is then placed in a heating block (at 145 ° C for 4 minutes). The tube is then cooled using an ice / water bath and the remaining radioactivity is measured.
- the reaction mixture obtained, dark in color, is then analyzed by radiochromatography.
- the incorporation yields are calculated from the TLC radiochromatogram and are defined by the area ratio of the tert-butyl ester derivative of [3- (2- [ 18 F] fluoro-pyridin-3-yloxy) -propyl acid. ] - carbamic on the total activity of 18 F fluor-18 (Si0 2 -CCM; eluent: EtOAc; Rf:: 0.75 and Rf: fluoride ion [ 18 F]: 0.0).
- the reaction mixture is diluted with 1 ml of water and transferred to a C18 Sep-pak (waters) cartridge.
- the tube is rinsed twice with 1 mL of water, which is also transferred and added to the diluted reaction mixture on the cartridge.
- the assembly is then passed through the cartridge.
- the cartridge is washed with 3 ml of water and partly dried for 0.5 minutes, sending a stream of nitrogen.
- the tert-butyl ester derivative of • [3- (2- [ 18 F] fluoro-pyridin-3-yloxy) -propyl] - carbamic acid is eluted from the cartridge with 3 mL of dichloromethane in a reaction flask containing 0.1 mL of TFA. 2 ml of dichloromethane are used twice to wash the cartridge and to completely transfer the derivative labeled with [ 18 F] mentioned above (5% of the amount of total radioactivity, involved in the fluorination process, remains on the cartridge) .
- the incorporation yield is also confirmed after the elution of Sep-pak by the ratio of the count values of CH 2 C1 2 to total eluted radioactivity (DMSO / H 2 0 + CH 2 C1 2 ).
- the resulting CH 2 C1 2 / TFA solution (50/1, V / V) is concentrated to dryness (at 65-75 ° C) under a moderate stream of nitrogen for 4 to 6 minutes).
- the deprotection yield is quantitative: No molecule, described above, protected by BOC can be detected by radiochromatography.
- the residue, above, is redissolved in 2 mL of CH 2 C1 and concentrated again to dryness to minimize the presence of TFA (at 65-75 ° C under a moderate stream of nitrogen for 4 to 6 minutes).
- the residue is then diluted with 0.5 mL of xylene containing 25 mg of N-methoxycarbonylmaleimide.
- the container is then hermetically closed, heated for 5 minutes at 190 ° C (strong reflux), then cooled for 2 minutes, using an ice / water bath.
- the reaction mixture is then injected onto a column of semi-preparative HPLC. Isocratic elution [eluent: heptane / EtOAc: 50/50; flow rate: 6.0 mL / minute] which gives 1- (3- (2- [ 18 F] fluor-pyridin-3-yloxy) -propyl] -pyrrole-2, 5- labeled dione, pure, retention time: 7.5 to 8.0 minutes.
- 60 to 70 mCi of 1- [3- (2- [ 18 F] fluor-pyridin-3-yloxy) -propyl] -pyrrole-2, 5-dione labeled, pure can be obtained in 75 to 85 minutes , from 550-650 mCi of a production batch
- the compound labeled with fluorine-18, 1- [3- (2- [ 18 F] fluoro-pyridin-3-yloxy) -propyl] -pyrrole-2, 5-dione can also be prepared by repeating steps in) and b) of the process described in Example 7, still using as labeling precursor, the compound “nitro” (tert-butyl ester of [3- (2-nitro-pyridin-3-yloxy) -propyl] acid] -carbamic), but by modifying the final part of the preparation (step c)) in the following way (variant according to which step c) is carried out in a biphasic mixture of dioxane and aqueous sodium bicarbonate).
- the cartridge is washed with 3 mL of water and partially dried for 0.5 minutes, sending a stream of nitrogen.
- the derivative labeled with fluorine-18 (1- [3- (2- [ 18 F] fluoro-pyridin-3-yloxy) -propyl] -pyrrole-2, 5-dione) is eluted from the cartridge with 3 mL of dichloromethane in a new empty vial. 1 ml of dichloromethane is used twice to wash the cartridge and to completely transfer the derivative labeled with [ 18 F] mentioned above.
- the solution containing the derivative labeled with [ 18 F] mentioned above is concentrated (at 65-75 ° C, under a moderate stream of nitrogen for 3 to 5 minutes) to a volume of approximately 1 mL and injected on a column of semi-preparative HPLC.
- the purification is identical to that described in Example 7.
- the fluorine-18 labeled compound, 1- [3- (2- [ 18 F] fluoro-pyridin-3-yloxy) -propyl] -pyrrole-2,5-dione can also be prepared by repeating steps a) and b) of the process described in Example 7 or 7a, but using as labeling precursor, the compound "trimethylammonium-trifluoromethane sulfonate” (trifluoromethanesulfonate of [3- (3-tert- butoxycarbonylamino-propoxy) -pyridin-2-yl] -trimethyl- ammonium).
- a peptide namely the peptide N-acetyl-Lys-Ala-Ala-Ala-Cys-amide
- a compound according to the invention which is 1- [3 - (2- [ 18 F] fluor-pyridin-3-yloxy) -propyl] -pyrrole-2, 5-dione.
- the labeled peptide is purified by HPLC on column C18 with a gradient of 0 to 34% acetonitrile / 0.1% TFA in
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pyridine Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nuclear Medicine (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03761670A EP1517903A2 (fr) | 2002-07-01 | 2003-06-30 | Composes de maleimides marques, leur procede de preparation et leur utilisation pour le marquage de macromolecules |
CA2491193A CA2491193C (fr) | 2002-07-01 | 2003-06-30 | Composes de maleimides marques, leur procede de preparation et leur utilisation pour le marquage de macromolecules |
US10/517,612 US7456202B2 (en) | 2002-07-01 | 2003-06-30 | Marked maleimide compounds, method for preparing same and use thereof for marking macromolecules |
JP2004516901A JP2006504640A (ja) | 2002-07-01 | 2003-06-30 | 標識したマレイミド化合物、それを調製する方法および高分子を標識するためのその使用 |
AU2003259312A AU2003259312A1 (en) | 2002-07-01 | 2003-06-30 | Marked maleimide compounds, method for preparing same and use thereof for marking macromolecules |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR02/08203 | 2002-07-01 | ||
FR0208203A FR2841554B1 (fr) | 2002-07-01 | 2002-07-01 | Composes de maleimides marques, leur procede de preparation et leur utilisation pour le marquage de macromolecules |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004002984A2 true WO2004002984A2 (fr) | 2004-01-08 |
WO2004002984A3 WO2004002984A3 (fr) | 2004-04-22 |
Family
ID=29725044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2003/002028 WO2004002984A2 (fr) | 2002-07-01 | 2003-06-30 | Composes de maleimides marques, leur procede de preparation et leur utilisation pour le marquage de macromolecules |
Country Status (7)
Country | Link |
---|---|
US (1) | US7456202B2 (fr) |
EP (1) | EP1517903A2 (fr) |
JP (1) | JP2006504640A (fr) |
AU (1) | AU2003259312A1 (fr) |
CA (1) | CA2491193C (fr) |
FR (1) | FR2841554B1 (fr) |
WO (1) | WO2004002984A2 (fr) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2036981A1 (fr) * | 2007-09-12 | 2009-03-18 | Bayer Schering Pharma Aktiengesellschaft | Aptamères étiquetés avec 18F |
WO2010114723A1 (fr) * | 2009-03-30 | 2010-10-07 | Ge Healthcare Limited | Réactifs et procédés de radiomarquage |
KR101229929B1 (ko) * | 2010-05-28 | 2013-02-05 | 서강대학교산학협력단 | 1,2,3-트리아졸기를 갖는 새로운 말레이미드 화합물, 이의 제조방법 및 이를 보결그룹으로 하는 생체화합물의 f18 표지방법 |
TWI410396B (zh) * | 2005-05-23 | 2013-10-01 | Nihon Mediphysics Co Ltd | A new method for the production of organic compounds and the use of the compounds for radioactive halogen calibration of organic compounds |
KR20160110500A (ko) | 2014-03-12 | 2016-09-21 | 아사히 가세이 가부시키가이샤 | 수지 조성물 및 그의 시트상 성형체 |
US11878968B2 (en) | 2021-07-09 | 2024-01-23 | Plexium, Inc. | Aryl compounds and pharmaceutical compositions that modulate IKZF2 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2008010953A (es) * | 2006-02-28 | 2008-09-08 | Amgen Inc | Derivados de cinolina y quinoxalina como inhibidores de la fosfodiesterasa 10. |
US7902332B2 (en) * | 2006-11-30 | 2011-03-08 | General Electric Company | Fluorine-labeled compounds |
FR2909881A1 (fr) * | 2006-12-14 | 2008-06-20 | Inst Nat Sante Rech Med | Nouveaux conjugues, utilisables a des fins therapeutiques, et/ou a titre d'agent de diagnostic et/ou d'imagerie et leur procede de preparation |
FR2926079B1 (fr) | 2008-01-03 | 2012-12-28 | Commissariat Energie Atomique | Procede de preparation d'un derive de purine marque, ledit derive et ses utilisations |
US11117858B2 (en) * | 2017-01-11 | 2021-09-14 | The General Hospital Corporation | Voltage gated sodium channel imaging agents |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62277331A (ja) * | 1986-04-21 | 1987-12-02 | ネオルツクス コ−ポレイシヨン | 蛋白質標識のための放射性ハロゲン化小分子 |
US4735792A (en) * | 1987-04-28 | 1988-04-05 | The United States Of America As Represented By The United States Department Of Energy | Radioiodinated maleimides and use as agents for radiolabeling antibodies |
US5242680A (en) * | 1991-08-23 | 1993-09-07 | Merck & Co., Inc. | Thiol-reactive maleimido-based radiolabeling reagents |
JPH09165377A (ja) * | 1995-12-15 | 1997-06-24 | Seitai Kinou Kenkyusho:Kk | 新規2−フルオロ芳香環−n1置換イミダゾール化合物およびその[18f]フッ素標識体 |
JP3992923B2 (ja) * | 1997-09-03 | 2007-10-17 | イムノメディクス, インコーポレイテッド | F−18陽電子放出トモグラフィー用のタン白及びペプチドのフッ素化方法 |
JPH11243984A (ja) * | 1998-03-04 | 1999-09-14 | Ikeda Shokken Kk | 6−[18f]フルオロ−l−ドーパの合成方法 |
US6743925B1 (en) * | 1999-09-13 | 2004-06-01 | Pola Chemical Industries, Inc. | Nitroimidazole derivative and diagnostic imaging agent containing the same |
FR2841558B1 (fr) * | 2002-07-01 | 2004-08-13 | Commissariat Energie Atomique | Peptides marques ayant une affinite pour un phospholipide et utilisations |
-
2002
- 2002-07-01 FR FR0208203A patent/FR2841554B1/fr not_active Expired - Fee Related
-
2003
- 2003-06-30 JP JP2004516901A patent/JP2006504640A/ja active Pending
- 2003-06-30 US US10/517,612 patent/US7456202B2/en not_active Expired - Fee Related
- 2003-06-30 CA CA2491193A patent/CA2491193C/fr not_active Expired - Fee Related
- 2003-06-30 AU AU2003259312A patent/AU2003259312A1/en not_active Abandoned
- 2003-06-30 EP EP03761670A patent/EP1517903A2/fr not_active Withdrawn
- 2003-06-30 WO PCT/FR2003/002028 patent/WO2004002984A2/fr active Application Filing
Non-Patent Citations (1)
Title |
---|
WILBUR D S: "Bioconjugate Chemistry", vol. 3, 1 November 1992, AMERICAN CHEMICAL SOCIETY, article "Radiohalogenation of proteins : an overview of radionuclides, labeling methods, and reagents for conjugate labeling", pages: 433 - 470 |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI410396B (zh) * | 2005-05-23 | 2013-10-01 | Nihon Mediphysics Co Ltd | A new method for the production of organic compounds and the use of the compounds for radioactive halogen calibration of organic compounds |
EP2036981A1 (fr) * | 2007-09-12 | 2009-03-18 | Bayer Schering Pharma Aktiengesellschaft | Aptamères étiquetés avec 18F |
US8530620B2 (en) | 2009-03-30 | 2013-09-10 | Ge Healthcare Limited | Radiolabelling reagents and methods |
CN102356069A (zh) * | 2009-03-30 | 2012-02-15 | 通用电气健康护理有限公司 | 放射性标记的试剂和方法 |
JP2012522052A (ja) * | 2009-03-30 | 2012-09-20 | ジーイー・ヘルスケア・リミテッド | 放射性標識試薬及び方法 |
US20120022227A1 (en) * | 2009-03-30 | 2012-01-26 | Dag Erlend Olberg | Radiolabelling reagents and methods |
WO2010114723A1 (fr) * | 2009-03-30 | 2010-10-07 | Ge Healthcare Limited | Réactifs et procédés de radiomarquage |
CN102356069B (zh) * | 2009-03-30 | 2014-09-24 | 通用电气健康护理有限公司 | 放射性标记的试剂和方法 |
CN104292155A (zh) * | 2009-03-30 | 2015-01-21 | 通用电气健康护理有限公司 | 放射性标记的试剂和方法 |
KR101229929B1 (ko) * | 2010-05-28 | 2013-02-05 | 서강대학교산학협력단 | 1,2,3-트리아졸기를 갖는 새로운 말레이미드 화합물, 이의 제조방법 및 이를 보결그룹으로 하는 생체화합물의 f18 표지방법 |
KR20160110500A (ko) | 2014-03-12 | 2016-09-21 | 아사히 가세이 가부시키가이샤 | 수지 조성물 및 그의 시트상 성형체 |
US10119017B2 (en) | 2014-03-12 | 2018-11-06 | Asahi Kasei Kabushiki Kaisha | Resin composition and sheet-shaped molded body thereof |
US11878968B2 (en) | 2021-07-09 | 2024-01-23 | Plexium, Inc. | Aryl compounds and pharmaceutical compositions that modulate IKZF2 |
Also Published As
Publication number | Publication date |
---|---|
AU2003259312A1 (en) | 2004-01-19 |
US7456202B2 (en) | 2008-11-25 |
WO2004002984A3 (fr) | 2004-04-22 |
US20050249662A1 (en) | 2005-11-10 |
EP1517903A2 (fr) | 2005-03-30 |
CA2491193C (fr) | 2013-04-16 |
FR2841554B1 (fr) | 2008-01-18 |
CA2491193A1 (fr) | 2004-01-08 |
JP2006504640A (ja) | 2006-02-09 |
FR2841554A1 (fr) | 2004-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4166142A1 (fr) | Composé de benzobisoxazole à substitution méthyle et son utilisation | |
US10112974B2 (en) | Method for the production of 18F-labeled active esters and their application exemplified by the preparation of a PSMA-specific PET-tracer | |
CA3139806A1 (fr) | Chelateurs macrocycliques et leurs procedes d'utilisation | |
JP6968809B2 (ja) | ジアリールヨードニウム塩を使用してヨード−又はアスタトアレーンを合成するための方法 | |
US11731917B2 (en) | Production method for radiolabeled aryl compound | |
KR20200006087A (ko) | 이관능성 킬레이트 및 그의 용도의 약동학적 증진 | |
Mushtaq et al. | Critical analysis of radioiodination techniques for micro and macro organic molecules | |
WO2004002984A2 (fr) | Composes de maleimides marques, leur procede de preparation et leur utilisation pour le marquage de macromolecules | |
Chiotellis et al. | Synthesis and biological evaluation of 18F-labeled fluoropropyl tryptophan analogs as potential PET probes for tumor imaging | |
EP2993171A1 (fr) | Procédé pour la production des traceurs PET spécifique PSMA | |
CA2710900C (fr) | Procede de preparation d'un derive de purine marque, ledit derive et ses utilisations | |
US20210115012A1 (en) | Radiolabeled cannabinoid receptor 2 ligand | |
TWI764977B (zh) | 作爲caspase抑制劑的聯環化合物、含有其的藥物組合物及其應用 | |
EP1517919B9 (fr) | Peptides marques ayant une affinite pour un phospholipide et utilisations | |
Koren et al. | Synthesis and initial in vitro characterization of 6‐[18F] fluoro‐3‐(2 (S)‐azetidinylmethoxy) pyridine, a high‐affinity radioligand for central nicotinic acetylcholine receptors | |
JPH10500953A (ja) | 画像診断用の芳香族アミンで置換された橋かけ窒素および硫黄供与体原子配位子 | |
JP2003306489A (ja) | ピロールピリジン誘導体放射性化合物 | |
CA2309795A1 (fr) | Produits radiopharmaceutiques utiles pour le marquage selectif des lymphocytes et leur preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003761670 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10517612 Country of ref document: US Ref document number: 2004516901 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2491193 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 2003761670 Country of ref document: EP |